CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
BOSTON, Nov. 08, 2017 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast corporate presentations at the following investor conferences in November:
- Stifel’s 2017 Healthcare Conference in New York City on Tuesday, November 14, 2017 at 3:30 p.m. ET
- Jefferies’ 2017 Global Healthcare Conference in London, UK, on Thursday, November 16, 2017 at 8:40 a.m. GMT (3:40 a.m. ET)
- A fireside chat at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 at 2:00 p.m. ET
Live audio webcasts of the presentations will be accessible from Keryx Biopharmaceuticals’ website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentations.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of more than 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets.
KERYX BIOPHARMACEUTICALS CONTACT:
Lora Pike
Senior Director, Investor Relations & Corporate Communications
T: 617-466-3511
[email protected]
